RAS oncogenes: the first 30 years

By Marcos Malumbres, M. Barbacid. Nature Reviews. Cancer, 2003

1,879 citations recorded by the source corpus.

Subfields: Cell Biology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/efc0cfb54f6b48f31b2935b05a14d607ab84f51c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cell Biology

1. Alec C. Kimmelman
2. C. Der
3. Joshua T. Mendell
4. N. Bardeesy

In Molecular Biology

1. Frank J. Slack
2. Joshua T. Mendell
3. Eric S. Lander
4. Carlo Maria Croce
5. Gad Getz
6. Alec C. Kimmelman
7. N. Bardeesy
8. Matthew Meyerson

In Oncology

1. Gad Getz
2. Nicolas Stransky
3. Alec C. Kimmelman
4. C. Der
5. R. DePinho
6. Joshua T. Mendell
7. N. Bardeesy
8. J. Wargo

Citations in the corpus

• RAS is regulated by the let-7 microRNA family. (2005, background): “elegans ortholog of human HRAS, KRAS, and NRAS (Figures S3A and S3B), which are commonly mutated in human cancer (Malumbres and Barbacid, 2003), including lung cancer.”
• Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. (2004, background): “Approximately 15% of human cancers have activating RAS mutationsSummary (Malumbres and Barbacid, 2003), and recently mutations in B-RAF were identified in a large-scale screenOver 30 mutations of the B-RAF gene associated with for genes mutated in human cancer (Davies et al., 2002).human cancers…”
• A Landscape of Driver Mutations in Melanoma (2012, background): “We also observed a known RAS familyactivating mutation (G12D) (reviewed in Malumbres and Barbacid, 2003) in a gene encoding for another Rho family GTPase member, CDC42 (Figure 3B).”
• Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. (2006, background): “Raf kinase is a member of a large protein complex that includes 14-3-3, RKIP, KSR, CNK, Spred, and SURB proteins (27, 28).”
• Pathological roles of MAPK signaling pathways in human diseases. (2010, background): “Indeed, K-Ras mutations have been detected in ~50% of colon cancers, in which mutations of N-Ras are rare [8].”
• OncodriveCLUST: exploiting the positional clustering of somatic mutations to identify cancer genes (2013, background): “…predominantly occur at specific protein residues or active domains; for example, most KRAS mutations are found in residues 12 and 13 of the protein (Malumbres and Barbacid, 2003), and mutations in PIK3CA are predominantly found in the kinase and helical domains of the PIK3CA subunit (Karakas et…”
• The let-7 microRNA represses cell proliferation pathways in human cells. (2007, background): “Our previous work showed that let-7 may directly control cellular proliferation by negatively regulating the human RAS genes (5), which are known lung cancer oncogenes (21).”
• A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes (2006, background): “…tumor suppressors such as retinoblastoma 1 (RB1) and p53 and oncogenes such asMYC and RAS have been extensively studied and found to be involved in complicated interacting pathways that regulate cell-cycle progression and apoptosis (Dang, 1999; Hickman et al., 2002; Malumbres and Barbacid, 2003).”